Evidence map›Paper›PMID 34151119›Full record

ArticleACS omega2021

Discovery and Optimization of Highly Potent and Selective AT

Yanghui Guo, Xiangui Huang, Weiwei Liao, Lichen Meng, Daiwang Xu, Cheng Ye, Lei Chen, Taishan Hu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. The Angiotensin ATPharmacological reviews · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yanghui GuoShanghai Institute of Drug Discovery, Zhejiang Hisun Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China.ORCID https://orcid.org/0000-0003-0320-946X
Xiangui HuangShanghai Institute of Drug Discovery, Zhejiang Hisun Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China.
Weiwei LiaoShanghai Institute of Drug Discovery, Zhejiang Hisun Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China.
Lichen MengShanghai Institute of Drug Discovery, Zhejiang Hisun Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China.
Daiwang XuShanghai Institute of Drug Discovery, Zhejiang Hisun Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China.
Cheng YeShanghai Institute of Drug Discovery, Zhejiang Hisun Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China.
Lei ChenShanghai Institute of Drug Discovery, Zhejiang Hisun Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China.
Taishan HuShanghai Institute of Drug Discovery, Zhejiang Hisun Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China.
Zhejiang Hisun Pharmaceutical (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The angiotensin II type 2 receptor (AT

Identifiers

PMID34151119
PMCPMC8210434
OpenAlexW3169849956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.